Cogent Biosciences, Inc. COGT Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$328.94M-28.6% | -$255.86M-33.0% | -$192.41M-37.2% | -$140.24M-94.0% | ||
| $2.56M+4.7% | $2.45M+7.9% | $2.27M+170% | $842K+473% | ||
| $46.08M+16.0% | $39.74M+29.8% | $30.62M+66.7% | $18.37M+57.2% | ||
| $601K— | $0— | $0— | —— | ||
| —— | $0+100% | -$8K— | $0— | ||
| -$2.51M— | —— | $4.81M— | —— | ||
| $10.69M-33.0% | $15.96M+95.3% | $8.17M-14.8% | $9.59M+179% | ||
| $195K— | —— | —— | —— | ||
| $33K— | $0— | $0— | —— | ||
| $2.02M+6.2% | $1.9M+44.2% | $1.32M-73.8% | $5.04M— | ||
| -$7.18M— | $0— | $0— | —— | ||
| -$264.44M-27.3% | -$207.79M-35.3% | -$153.62M-29.5% | -$118.64M-102% | ||
| $1.55M+171% | $573K-79.5% | $2.8M-59.3% | $6.86M— | ||
| -$399.53M-1,144% | $38.28M— | —— | —— | ||
| $54.64M— | $0— | $0— | —— | ||
| $11.55M— | $0— | —— | $0— | ||
| $48.9M— | $0— | $0— | —— | ||
| $878.23M+309% | $214.71M+31.3% | $163.54M0.0% | $163.56M— | ||
| $216.23M— | —— | -$87.91M-10.2% | -$79.8M— | ||
| —— | $7.62M— | —— | —— | ||
| $601K— | $0— | $0— | —— | ||
| $2.56M+4.7% | $2.45M+7.9% | $2.27M+170% | $842K— | ||
| $10.69M-33.0% | $15.96M+95.3% | $8.17M-14.8% | $9.59M+179% | ||
| -$1.57M-12.9% | -$1.39M-74.1% | -$796K+91.1% | -$8.97M-337% | ||
| -$1.56M— | —— | $119K— | —— | ||
| $195K— | —— | —— | —— | ||
| $2.02M+6.2% | $1.9M+44.2% | $1.32M-73.8% | $5.04M— | ||
| $223.1M— | $0— | $0— | —— | ||
| —— | —— | —— | —— | ||
| —— | $0— | $0— | $0-100% | ||
| $54.64M— | $0— | $0— | —— | ||
| —— | —— | —— | $19.57M— | ||
| —— | $0— | —— | $58K— | ||
| -$266M-27.7% | -$208.36M-33.2% | -$156.42M-24.6% | -$125.5M— | ||
| -$266M-27.7% | -$208.36M-33.2% | -$156.42M-24.6% | -$125.5M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Cogent Biosciences, Inc. generate?
- Cogent Biosciences, Inc. (COGT) generated -$284.8M in operating cash flow over the trailing twelve months.
- What is Cogent Biosciences, Inc.'s free cash flow?
- After $1.5M of capital expenditures, Cogent Biosciences, Inc.'s free cash flow was -$286.3M over the trailing twelve months, down 28.5% year over year.
- Where does Cogent Biosciences, Inc.'s cash flow data come from?
- Every line is extracted from Cogent Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
